Obesity is associated with increased risk of positive surgical margins and prostate specific antigen (PSA) recurrence among men undergoing radical prostatectomy. To what degree positive margins contribute to poorer outcome is unclear. Thus, we sought to examine the association between body mass index (BMI) and more objective measures of tumor aggressiveness, tumor grade and size. We carried out a retrospective analysis of 2302 patients treated with radical prostatectomy at the Duke Prostate Center from 1988-2007. Tumor volume was calculated by multiplying prostate weight by percent of specimen involved with cancer. Associations between BMI and tumor volume and highgrade disease (GleasonX4 þ 3) independent of pre-operative clinical characteristics of age, race, PSA, clinical stage, biopsy Gleason sum, and year of surgery were assessed using linear and logistic regression, respectively. Mean and median BMI among all subjects was 28.1 and 27.6 kg m -2 , respectively. Increased BMI was significantly associated with younger age (Po0.001), black race (Po0.001), more recent year of surgery (Po0.001), and positive surgical margins (Po0.001). After adjusting for multiple clinical pre-operative characteristics, higher BMI was associated with a greater percent of the prostate involved with cancer (P ¼ 0.003), increased tumor volume (Po0.001), and high-grade disease (P ¼ 0.007). Men with a BMI X35 kg m 2 had nearly 40% larger mean tumor volumes than normal weight men (5.1 versus 3.7 cc), after adjustment for multiple clinical characteristics. In this study, obese men undergoing radical prostatectomy had higher-grade and larger tumors, providing further evidence that obese men undergoing radical prostatectomy have more aggressive prostate cancers.
Introduction
Obesity has become too common, affecting one-third of all adults in the United States. The adverse health consequences of obesity are well documented. In terms of prostate cancer, obesity has been associated with increased risk of prostate specific antigen (PSA) recurrence after radical prostatectomy 1, 2 and increased risk of prostate cancer death. 3 Although these findings certainly support the hypothesis that obesity is related to aggressive tumor biology, it is to be noted that alternative explanations for these observations exist. For example, obesity is associated with technical challenges in carrying out radical prostatectomy 4 contributing to increased risk of positive surgical margins. 5 Thus, the increased recurrence risk after surgery may, in part, be attributable to technical issues unrelated to tumor biology. In regards to the increased risk of prostate cancer death, recent data suggest that obese men are less likely to receive aggressive therapy and more likely to receive primary androgen deprivation. 6 Given the prostate cancer-specific survival detriment associated with primary androgen deprivation relative to observation 7 and the improved survival with treatment relative to observation, 8 it is possible that greater use of primary androgen deprivation among obese men and less use of aggressive treatment could contribute to poor prostate cancer specific survival. Although the degree to which aggressive treatment improves prostate cancer survival can be debated, it nonetheless remains possible that poorer prostate cancer survival may in part be because of factors unrelated to tumor biology.
Our underlying hypothesis is that, obesity is associated with more aggressive disease biology. 9 However, as noted, alternative explanations exist for the poorer outcomes among obese men noted in earlier studies. As such, we sought to provide objective measures of aggressive tumor biology in a cohort of men all treated aggressively for clinical localized prostate cancer. To this end, we examined the association between body mass index (BMI) and pathological tumor grade, percent of the prostate involved with cancer, and tumor volume in a cohort of men treated with radical prostatectomy at a single institution. Of note, this is a cohort in which we have already shown that obesity, independent of stage and grade, is a significant predictor of PSA progression. 10 
Materials and methods

Study population
After obtaining Institutional Review Board approval, data from patients treated with radical prostatectomy between 1988 and 2007 at Duke University Medical Center were abstracted into the Duke Prostate Center (DPC) database. This database includes information on patient age at the time of surgery, race, height, weight, clinical stage, grade of cancer on diagnostic biopsies, preoperative PSA concentration, surgical specimen pathology (specimen weight, tumor volume, grade, stage, and surgical margin status), and follow-up PSA data for a mean and median of 4.7 and 4.0 years (range: 0.1-16.3 years). Of the 4221 patients in the DPC radical prostatectomy Database, a total of 2384 had BMI and tumor volume data available for analysis. Of these, we excluded patients with missing data for pre-operative PSA (n ¼ 80), and race (n ¼ 2), resulting in a final study population of 2302 men.
The prostatectomy specimens were harvested in the operating room, left and right sides inked with different colors, weighed, and fixed in formaldehyde overnight at 4 1C. The apex and the bladder neck margin were shaved and radially sectioned to permit evaluation of the margin status parallel to the urethra. The remaining prostate was then sectioned perpendicular to the rectal surface at 3-4 mm intervals, and submitted entirely for microscopic evaluation. Paraffin-embedded, hematoxylin and eosin stained sections were prepared in the usual manner. In a few difficult cases, immunohistochemical stains for amethylacyl CoA racemase and cytokeratin 34bE12 were carried out on selected slides. The percent tumor involvement of the prostate was determined as described earlier. 11 In brief, the percent involvement of each slide was estimated in quintiles as 0-20%, 20-40%, 40-60%, 60-80%, or 80-100%. Estimation of tumor volume for the entire prostate was accomplished by summing and averaging the volume quintile on each slide and then multiplying by the specimen weight.
Statistical analysis
Body mass index, abstracted from the peri-operative anesthesia records, was calculated according to the following equation: BMI ¼ weight (kg)/height (m) ) into the following groups: o25 (normal weight), 25-29.9 (overweight), 30-34.9 (mildly obese), and X35 (moderately or severely obese).
Clinical and pathological characteristics among BMI groups were compared using analysis of variance or Kruskall-Wallis for continuous variables depending on whether they were normally distributed or not and the w 2 test for categorical variables. The associations between BMI and percent of prostate involved with cancer, tumor volume and high-grade pathological disease (Gleason X4 þ 3) were estimated using linear and logistic regression analysis, respectively. As tumor volume and percent involvement of the prostate were not normally distributed, we examined them after logarithmic transformation. We mutually adjusted for PSA (continuous after logarithmic transformation), age at radical prostatectomy (continuous), clinical stage (T1 versus T2/T3), year of surgery (continuous), biopsy Gleason score (2-6, 3 þ 4, and X4 þ 3), and race (black versus non-black). To determine the P-trend, all members of each BMI subgroup were assigned the median BMI value for their respective subgroup and all regression analyses were recalculated with BMI as a continuous variable. To determine mean adjusted percent tumor involvement and tumor volume, we computed the mean logarithmically transformed value adjusted for the multiple clinical covariates and results were then back transformed for ease of interpretation.
All statistical analyses were carried out using STATA 10.1 (College Station, TX, USA).
Results
Patient demographics
Mean and median BMI among all subjects was 28.1 and 27.6 kg m -2 , respectively. The majority of patients were white, had clinical stage T1c disease, biopsy Gleason o7 tumors, and PSA values o10 ng ml -1 . Patients with higher BMI were treated in more recent years (Po0.001), were more likely to be black (Po0.001), were significantly younger (Po0.001), had lower PSA values (P ¼ 0.02), larger prostate weights (P ¼ 0.02), larger tumor volumes (P ¼ 0.04), and higher rates of positive surgical margins (Po0.001, Table 1 ). In addition, there were trends towards higher rates of extracapsular extension (P ¼ 0.08) and a greater percent of the prostate involved with cancer (P ¼ 0.06) among men with higher BMI values, though these did not reach statistical significance. There was no significant association between BMI and Gleason grade. Similarly, BMI was not significantly related to seminal vesicle invasion or lymph node metastasis, though the number of men with these adverse features was small.
Obesity and tumor grade
After controlling for multiple clinical characteristics, higher BMI was independently associated with highgrade disease (P ¼ 0.007; Table 2 ). Men with a BMI X35 kg m -2 were over 50% more likely to have high-grade disease than men with a normal body weight (BMI o25 kg m -2 ).
Obesity and tumor volume
After controlling for multiple clinical characteristics, higher BMI was independently associated with greater percent of the prostate involved with cancer (P ¼ 0.003; . Similarly, higher BMI was significantly associated with larger tumor volume (Po0.001; Table 3 ). Tumor volumes in men with a BMIX35 kg m -2 were nearly 40% larger then men with a BMI p25 kg m -2 (5.1 versus 3.7 cc).
Given, men with a higher BMI had both a larger prostate size and greater percent involvement, we sought to examine whether this association was driven by a generalized association between larger prostate size and greater percent involvement created by differential 
Discussion
Obesity is associated with increased risk of biochemical recurrence after radical prostatectomy 1,2 and increased risk of prostate cancer death. 3 However, there are possible non-biological explanations for these findings including poor surgical technique in obese men contributing to higher positive margin rates 4, 5 and less aggressive treatment for obese men, respectively. 6 Thus, we sought to examine the obesity-prostate cancer relationship using more objective measures: tumor grade and tumor burden. In this analysis of over 2000 men treated with radical prostatectomy we found obesity was associated with significantly higher-tumor grades, greater involvement of the prostate with cancer, and larger tumors. These findings lend further support to the underlying hypothesis that obesity is associated with more aggressive disease biology.
Much has been written about the association between obesity and prostate cancer. 9 Although a lot of the data seems conflicting, particularly for overall prostate cancer risk, there is a consensus emerging that obesity may be associated with more aggressive prostate cancer. This is evidenced by higher-grade disease in men undergoing biopsy 12, 13 and in those treated with radical prostatectomy, 1,2 greater biochemical recurrence risk after surgery 1,2 and greater risk for development of death from prostate cancer. 3 Although these findings certainly implicate obesity as a significant risk factor for aggressive prostate cancer, the reasons for this remain unclear. However, it has been postulated that poor surgical technique, may contribute to the poorer outcomes after radical prostatectomy for obese men. 4, 5 Similarly, obese men are less likely to receive aggressive treatment, which theoretically could contribute to higher risk of cancer-specific death. 6 Thus, we surmised that objective data are needed to better assess the association between obesity and aggressive disease. To this end, we examined a cohort of over 2000 men with early stage disease all treated aggressively with radical prostatectomy.
Within this cohort, we found that obesity was significantly associated with higher-tumor grades, in line with earlier studies.
1,2 However, the new finding was that obesity was associated with greater involvement of the prostate with cancer, and larger tumors. Loeb et al. earlier found that obese men undergoing radical prostatectomy had larger tumor volumes than non-obese men.
14 However, given that obese men in general have larger sized prostates 15 and tumor volume reflects percent of the prostate involved multiplied by prostate size, it is unclear if the findings of Loeb et al. were driven by greater percent of the prostate involved with tumor or an equal percent of the prostate involved, just in a larger sized prostate. That being said, the lack of association between BMI and prostate size in the Loeb et al. study would suggest that obese men did indeed have a greater percent of the prostate involved with cancer. In the current study, not only did obese men have larger prostates, but they had more of the prostate involved with cancer. Given that larger prostates correlated with less tumor involvement, this association between obesity and greater percent tumor involvement seems particularly striking. As such, we believe these data provide further objective evidence that obese men have larger and more aggressive cancers.
Unfortunately, the biological underpinnings of the obesity-aggressive prostate cancer link remain unclear. In general, obese men have higher insulin levels than normal weight men, 16 and prostate cancers have recently been shown to express the insulin receptor at high levels. 17 Moreover, in multiple studies higher insulin levels among men with prostate cancer have been linked with prostate cancer death. 18, 19 In addition, obese men have lower androgen levels, which may promote more aggressive cancers, 20 though this remains a controversial hypothesis. Moreover, obesity is associated with a highcalorie, high-fat, high-refined carbohydrate diet, which may promote prostate cancer growth. 21 Ultimately, the molecular mechanisms linking obesity and aggressive prostate cancer, which are likely multifactorial, are an area ripe for further investigation.
This study has certain limitations. First, we limited our study to men undergoing radical prostatectomy. Although this creates a selection bias of which patients receive surgery, this was necessary as our outcome (tumor volume) is only available for men in whom the entire prostate was removed. We did not report on oncological outcomes within this study. However, we have done this earlier in this exact same cohort and noted that obese men are more likely to develop a biochemical recurrence, 10 though longer follow-up with more distal end-points such as metastasis and cancer death are needed. Finally, obese men have lower PSA values than normal weight men, 22 which theoretically could lead to delayed diagnosis. As such, this is a possible explanation for the larger sized tumors at ultimate diagnosis. However, in the absence of grade-progression this cannot explain the higher-grade tumors among obese men, again, providing some support to the hypothesis of more aggressive tumors among obese men.
Conclusions
In a cohort of over 2200 all treated aggressively with radical prostatectomy, we found that obese men had high-grade and larger tumors. These findings provide further support to the hypothesis that obese men undergoing radical prostatectomy have more aggressive prostate cancer.
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